Efficacy and safety of tafluprost-timolol fixed-dose combination in open-angle glaucoma and ocular hypertension

Résumé fourni par la source

Purpose To evaluate the efficacy and safety of tafluprost and timolol combination in open-angle glaucoma (OAG) and ocular hypertension (OHT). Methods PubMed, Embase, Scopus, ClinicalTrials.gov and Cochrane Library databases were searched from their inception until March 28, 2025. Meta-analysis was conducted utilizing the ‘metaprop’ and ‘metamean’ packages in R Studio (version 4.4.3). We pooled proportion or incidence rate along with the respective 95% confidence interval (CI) and mean difference with 95% CI for continuous outcomes using a random effects model. The I2 test was employed to assess heterogeneity between the studies. Results This meta-analysis included 15 studies involving 2066 patients. The pooled overall mean decrease in intraocular pressure (IOP) was −4.28 mmHg (95% CI: −6.21 to −2.34, I 2 = 98.1%). Subgroup analysis indicated a more substantial IOP reduction in treatment-naïve individuals of −7.81 mmHg (95% CI: −10.73 to −4.90, I 2 = 91.3%) when compared to the monotherapy switch group (−2.95 mmHg [95% CI: −5.09 to −0.81, I 2 = 98.2%]). The incidence of any adverse event was 16% (95% CI: 6% to 37%, I 2 = 96.2%), while incidence of serious adverse events was 2% (95% CI: 1% to 6%, I 2 = 54.6%) and discontinuations were at 2% (95% CI: 1% to 5%, I 2 = 52%). Conclusion The fixed-dose combination of tafluprost and timolol notably decreases IOP, particularly in treatment-naïve patients, while exhibiting minimal systemic side effects and a satisfactory safety profile, thus endorsing its clinical application in the management of glaucoma and ocular hypertension.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.